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Backround
Glycosylation of protein therapeutics is influenced by a
multifaceted mix of product intrinsic properties, host
cell genetics and upstream process parameters. Indus-
trial CHO cell lines may have several deficits in their
glycosylation pattern for some applications, like high
fucose content (corresponding to a low ADCC profile)
and low galactosylation and sialylation levels (proposed
to decrease activity and/ or pharmacokinetics).
We have successfully applied the GlymaxX® technol-
ogy [1] abolishing fucose synthesis in well-established
CHO DG44 and K1 platforms and pre-existing producer
cell lines (glycan modulator GM1). Here we extend this
strategy by other engineering approaches to enable pro-
duction of protein therapeutics with desired glycosyla-
tion features. Through stable integration of other genes
for glycosylation enzymes we are able to tune galactosy-
lation (glycan modulator GM2) and sialylation (glycan
modulator GM3). These glycan modulators can specifi-
cally be combined to address certain desired oligosac-
charide patterns.
We postulate that modulating effects of GM2 and GM3
require a specific expression level. In this case the combi-
nation of high level target protein expression and defined
levels of glycan modulators becomes extremely rare.
Therefore, the characterization of clones with individual
stable levels of glycanmodulator expression is a prerequi-
site for industrial application.
Materials and methods
Two vectors expressing either GM2 alone or GM2 and
GM3 in combination were constructed to evaluate modu-
lator effects. This technology was applied to both, CHO-
DG44 and K1 cells to generate modified host cell pools.
Modulator host cell clones were generated out of appro-
priate DG44 pools and characterized for growth and mod-
ulator gene expression using a 7-day shaker batch culture
and RT-qPCR respectively. A human IgG and a Fc-Fusion
protein carrying a single N-glycosylation side in the CH2
domain were chosen as model proteins. After stable trans-
fection of human IgG into GM2 and Fc-fusion protein
into GM2/3 clones, the resulting test modulator clone
pools were analyzed in fed batch shaker assays. Harvested
culture supernatants were purified and subjected
to N-Glycan profile analysis performed by Hydrophilic-
Interaction-Chromatography (HILIC).
Results
Characterization of modulator host cell clones for prolif-
eration and modulator mRNA expression indicated that
growth behavior is not influenced by modulator expres-
sion level. Therefore only GMx-mRNA level were used
to select five to six clones expressing a broad range of
either GM2 alone or GM2 and GM3 in combination.
Each selected modulator host cell clone was transfected
with the corresponding model protein in duplicates
(indicated by A or B).
Final fed batch assays gave typical clone pool results
with growth profiles showing high comparability between
clone pools expressing the same model protein (Table 1).
Peak viable cell densities (VCD) of about 3E7 vc/mL
were reached with maximum titers of 1.2 g/L hum IgG
and 2.4 g/L Fc-Fusion protein within 12 days, while final
viabilities were in most cases above 80%.Up to 3 fold dif-
ferent titers between pools A and B of the same starter
clone were observed depending on selection schemes and
process management.
As it is given by the conveyer like nature of the glyco-
sylation machinery the content of a certain glycan
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structure cannot be increased without decreasing the
output of the preliminary structures. Therefore the
hypergalactosylation effect of GM2 should result in a
shift towards more G2F structures and for the combina-
tion of GM2 and GM3 a shift towards more G2FS1
structures is anticipated, while even the G2F content
could be decreased. As shown in Figure 1 the expected
shifts were observed, demonstrating that the glycan
modulators are working in the intended way. Addition-
ally, we found a positive correlation between the level of
modulator gene expression and the degree of glycan
modifying effect. Clone pools with highest modulator
expression levels displayed the highest content of the
desired structures e.g. G2F for GM2 clones and G2FS1
for GM2/3 clones. This reflects a 15 - 20-fold increase
of these target structures compared to clone pools with
low or moderate modulator expression (Table 1).
Despite substantial differences in productivity and
process between A and B clone pool duplicates (2 - 3
fold difference in titers) in most cases only slight shifts
of certain oligosaccharide structures were observed (e.g.
clone pool 3 - 5 and 8, 9). This indicates that the glycan
pattern is more depended on clone specific modulator
gene expression than on glycoprotein expression level.
Conclusions
Expression of GM2 and GM3 in CHO cell lines can
effectively change the glycosylation pattern of target pro-
teins in a dose dependent manner. Growth and produc-
tivity characteristics are similar to unmodified host cells
and maintain their suitability for clinical and commercial
production.
The degree of glycomodulation is reproducible and rela-
tively independent of target glycoprotein expression level.
Table 1 Data of selected clone pools shown in Figure 1.
Model protein: human IgG Model protein: Fc-Fusion protein
Clone pool no. 1 2 4 6 7 10
Index A B A B A B A B A B A B
relative modulator mRNA expression
GM2 5.8 5.8 2.5 2.5 0.4 0.4 1.5 1.5 3.7 3.7 0.6 0.6
GM3 3.2 3.2 1.4 1.4 0.3 0.3
Key process parameter
Peak VCD (cell/mL) 20 20 31 24 28 24 31 24 29 25 27 25
Final-vitality (%) 73 82 82 88 87 91 87 87 86 84 89 93
Titer (g/L) 0.6 0.4 0.9 0.7 1.0 0.6 2.1 1.0 1.8 1.0 2.3 1.1
N-Glycan analysis
G0F (%) 2 1 62 55 71 68 37 24 19 19 46 41
G1F (%) 19 13 23 29 18 21 27 32 35 34 33 38
G2 (%) 3 4 1 1 1 1 1 1 1 1 1 1
G2F (%) 61 67 4 6 2 3 3 7 11 10 9 12
G1FS1 (%) 2 3 <1 <1 <1 <1 9 9 5 7 0 0
G2FS1 (%) 2 2 <1 <1 <1 <1 19 21 22 11 1 9
GM2 and human IgG expressing clone pools no. 1, 2, 4. Fc-Fusion protein and GM2/3 expressing clone pools no. 6, 7, 10. Duplicates are indicated by A and B.
Key process parameter and corresponding results of N-Glycan analysis are shown in the under part of the table.
Figure 1 HILIC chromatograms of clone pools with distinct
modulator expression levels. A: GM2 clone pools, B: GM2/3 clone
pools. With increasing GM2 activity a clear shift towards G2F
structures can be observed. While the increasing activities of GM2
and GM3 correlates positively with the G2FS1 content.
Winkler et al. BMC Proceedings 2013, 7(Suppl 6):P96
http://www.biomedcentral.com/1753-6561/7/S6/P96
Page 2 of 3
This allows a prediction of glycosylation patterns of glyco-
proteins produced in certain host cell clones in relation to
modulator expression level.
Finally, a comprehensive set of engineered, biophar-
maceutical CHO production cell lines were generated
and characterized, individually optimized for enhanced
ADCC activity, adjusted galactosylation or sialylation
levels of the target proteins. This elaborate cellular tool-
box allows the rapid and targeted creation of antibody
and glycoprotein molecules with specific pre-defined
glycan profiles.
Authors’ details
1ProBioGen AG, D-13086 Berlin, Germany. 2Christian-Albrechts-Universität zu
Kiel, D-24118 Kiel, Germany. 3Hochschule für Technik und Wirtschaft Berlin,
D-10138 Berlin, Germany.
Published: 4 December 2013
Reference
1. von Horsten HH, Ogorek C, Blanchard V, Demmler C, Giese C, Winkler K,
Kaup M, Berger M, Jordan I, Sandig V: Production of non-fucosylated
antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-
hexulose reductase. Glycob 2010, 20:1607-1618.
doi:10.1186/1753-6561-7-S6-P96
Cite this article as: Winkler et al.: CHO starter cell lines for
manufacturing of proteins with pre-defined glycoprofiles. BMC
Proceedings 2013 7(Suppl 6):P96.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Winkler et al. BMC Proceedings 2013, 7(Suppl 6):P96
http://www.biomedcentral.com/1753-6561/7/S6/P96
Page 3 of 3
